Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?
Jelle Matthijnssens, Osamu Nakagomi, Carl D Kirkwood, Max Ciarlet, Ulrich Desselberger, Marc Van Ranst
Expert Review of Vaccines | TAYLOR & FRANCIS LTD | Published : 2012
Awarded by National Health and Medical Research Council CDA fellowship
J Matthijnssens was supported by a 'Fonds voor Wetenschappelijk Onderzoek' postdoctoral fellowship. CD Kirkwood was supported by a National Health and Medical Research Council CDA fellowship (609347). J Matthijnssens and M Van Ranst were investigators in a postmarketing effectiveness study conducted in Belgium and sponsored by GlaxoSmithKline Biologicals. C Kirkwood is Director of the Australian Rotavirus Surveillance Program, which is supported by research grants from GlaxoSmithKline Biologicals and CSL. M Ciarlet was employed at Merck and Co., Inc. when the pivotal rotavirus efficacy and postmarketing effectiveness studies were performed, and owned stock in the company. U Desselberger was a member of the GSK-supported PROTECT group, which was dissolved in 2010. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apartfrom those disclosed.